The report on Psoriasis Therapeutics Market by molecule (biologics, small molecules), route of administration (oral, parenteral, topical), dosage forms (solid, liquid, EMI-solid ), mechanism of action (TNF inhibitors, PDE4 inhibitors, il blocker) trends analysis and forecasts up to 2023 studies the market sizes, key trends and opportunities in the main geographies such as North America, Europe, Asia-Pacific, Rest of the World. According to the report the Global Psoriasis Therapeutics Market is projected to grow at a CAGR of 9.7% in terms of value over the period of 2017-2023. The growth in the world market is primarily driven by significant contribution by North America (Leading region) region to this market.
Psoriasis is a common immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes buildup of thick white, red, or silvery patches of skin. It alters the normal cell cycle of the skin. The new cells of the skin grow and move quickly to the surface of the skin to form patches known as "plaques". The plaques are commonly found on knees, elbows, scalp, hands, and feet. Psoriasis occurs mostly in adults, but can also be seen in children and adolescents. The etiology of the disease is unknown, however, it is believed to be an immune-mediated process. Read more details at: http://www.bigmarketresearch.com/global-psoriasis-therapeutics-2015-2019-market
Systemic Psoriasis Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Systemic Psoriasis Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource.
The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research team of industry experts. Enquiry @ http://www.researchbeam.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market/enquire-about-report
Download Sample Brochure@ http://tinyurl.com/gnovyco Marketintelreports, ‘Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2016’, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects.
Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. Read more details at: http://www.bigmarketresearch.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market
The Psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination.
GBI Research, the leading business intelligence provider, has released its latest research, Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. Detailed Report at: http://www.reportsandintelligence.com/psoriasis-therapeutics-in-asia-pacific-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth-market
The latest updated report on the Global Psoriasis Drugs Market added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical
This report provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by the Research’s team of industry experts.
This report provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by a team of industry experts.
The Psoriasis market report thoroughly examines the market size, latest trends, and growth forecast. The report includes an overview of the disease and market scenario, as well as market trends, growth prospects, investment opportunities, and industry prospects. Additionally, it provides competitor analysis, regional analysis, and recent advancements in the Psoriasis market.
The Asia-Pacific Pruritus Therapeutics Market was valued at $2.0 billion in 2022 and is projected to reach $3.2 billion by 2032, registering a CAGR of 4.7% from 2023 to 2032.
Psoriasis Drug Market, [By Therapeutic Class (Interleukin Inhibitors, Tumour Necrosis Factor Inhibitors, Vitamin D-Analogues, Others); By Treatment Type (Topicals, Systematics, Biologics)]; and Geography - Trend, Analysis and Forecast
The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market. Read Complete Report @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Enquire @ http://www.researchbeam.com/anti-inflammatory-therapeutics-market/enquire-about-report
The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics.
The Global Autoimmune Disease Therapeutics Market size is expected to reach $149.4 billion by 2025, rising at a market growth of 4.34% CAGR during the forecast period. The autoimmune disease therapeutics market is anticipated to experience significant market growth during the forecast period due to early diagnosis of the disease, the latest launch of advanced therapy, and increased incidence of autoimmune disease. The market is witnessing a strong presence of late-stage pipeline drugs such as tocilizumab, baricitinib, olokizumab, apremilast, abatacept, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib, and others. On the other hand, higher costs associated with sophisticated therapy are anticipated to hamper the market growth. Full Report: https://www.kbvresearch.com/autoimmune-disease-therapeutics-market/
Infinium Global Research has added a new report on Global Psoriasis Therapeutics Market. The report predicts the market size of Psoriasis Therapeutics is expected to reach XX billion by 2023.
The report on Psoriasis Therapeutics by Infinium Global Research analyses the Psoriasis Therapeutics Market over the period of 2017 to 2023. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in Global Psoriasis Therapeutics Market. It will help a lot of decision makers to develop strategies and find new opportunities in the Global Psoriasis Therapeutics Market.
It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. For More Details: http://goo.gl/cSK8ZN
The autoimmune disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to grow at a CAGR of 7.60% in the above-mentioned forecast period. Increasing awareness regarding healthcare sector drives the autoimmune disease treatment market. https://www.databridgemarketresearch.com/reports/global-autoimmune-disease-treatment-market
Download Sample Brochure @ http://tinyurl.com/hrk5w6o Marketintelreports, ‘Psoriasis - Pipeline Review, H2 2015’, provides an overview of the Psoriasis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriasis and special features on late-stage and discontinued projects.
Global news:Plaque Psoriasis (Psoriasis Vulgaris) research 2023 by Gosreports. http://www.gosreports.com/global-automotive-surround-view-systems-market-research-report-2016/ http://www.gosreports.com/global-food-animal-eubiotics-market-research-report-2016/
Psoriasis is a complex, chronic, multifactorial, inflammatory disease that involves hyperproliferation of the keratinocytes in the epidermis, with an increase in the epidermal cell turnover rate.
Get a sample brochure @ http://tinyurl.com/zmc69dn The Asia-Pacific anti-inflammatory therapeutics market is expected to grow at a CAGR of 8.6% over the forecast period, owing to the rising healthcare expenditure, disposable income of individuals, increasing popularity of biologics and better healthcare access. Increase in the number of autoimmune and respiratory diseases, new drugs in development pipeline and increased usage of OTC NSAIDs are the major factors driving the Asia-Pacific anti-inflammatory market.
The global sleep apnea devices market is expected to grow at a CAGR of 16.6% during the forecast period of 2014 to 2019. North America is the largest market in the global sleep apnea devices market, with a market share of 51.8% as of 2013, followed by Europe and Asia. The global sleep apnea devices market is broadly classified on the basis of segments, namely sleep apnea therapeutic devices and sleep apnea diagnostic devices. See Full Report: http://bit.ly/1JaPNW6
Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis and urticaria is expected to drive market growth during the forecast period.
Big Market Research : World Anti-Inflammatory Therapeutics Market - Size, Share, Trends, Demand, Report, Opportunities and Forecast 2020 To Get More Details @ http://www.bigmarketresearch.com/anti-inflammatory-therapeutic-market Inflammation is triggered by the defense system of the body in response to harmful stimuli, damaged cells, irritants and microorganisms. Inflammation is the mechanism of innate immunity, which seeks to eliminate the cause of injury, clear dead and necrotic cells and heal injured tissues. Sometimes, the body defense system inappropriately triggers inflammation against its own cells, resulting in incurable inflammatory autoimmune diseases such as arthritis, asthma and chronic obstructive pulmonary disease (COPD). According to World Health Organization (WHO), approximately 235 million people suffer from asthma in the world.
Gene Therapy Oncology Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. See Full Report @ http://bit.ly/18JkhT4
We believe there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expect few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. In this report, we highlight the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compare their clinical trials data, and their commercial potential!
The report is an essential source of information and analysis on the global Narcolepsy Therapeutics market. The report identifies the key trends shaping and driving the global Narcolepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1wDZ3NU
The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: Germany, France, UK, Italy and Spain. For More Details: http://goo.gl/CnqBhQ
Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. See Full Report @ bit.ly/12yBegp
Straits Research has just produced a new research study on the Psoriasis Drug market, which helps to influence the future of organisations by making well-informed business choices.
The Pruritus market report thoroughly examines the market size, latest trends, and growth forecast. The report includes an overview of the disease and market scenario, as well as market trends, growth prospects, investment opportunities, and industry prospects. Additionally, it provides competitor analysis, regional analysis, and recent advancements in the Pruritus market.
According to the latest research report by IMARC Group, The global cytokine market size reached US$ 89.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 163.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.76% during 2024-2032. More Info:- https://www.imarcgroup.com/cytokine-market
The global dermatology diagnostic devices market size reached US$ 16.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 34.4 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032.
The global jojoba oil derivatives market size reached US$ 192.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 355.1 Million by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032.
The global autoinjector market is primarily driven by the increasing incidences of chronic and lifestyle diseases and the escalating demand for enhanced patient convenience. Additionally, individuals are rapidly shifting from conventional devices toward self-administrating devices, such as autoinjectors, due to the growing awareness regarding their benefits For an Executive Summary of Autoinjector Report Visit the following link: https://www.imarcgroup.com/autoinjector-market E-mail: sales@imarcgroup.com Contact: +91-120-415-5099
Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical..... @ @ https://bit.ly/3qztA1o
GBI Research has released the pharma report: “Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation”, which identifies and assesses first-in-class innovation in the psoriasis development pipeline. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-psoriasis-identifying-and-commercializing-first-in-class-innovation-market
The major players covered in the global oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S.... @ @ https://bit.ly/3gz5Nve
North America was the largest region in the biologics market in 2017, accounting for nearly 40% market share. Read report: https://www.thebusinessresearchcompany.com/report/biologics-global-market-report-2018
In the realm of skincare, the landscape is constantly evolving, driven by advancements in science, technology, and consumer preferences. One significant niche within this expansive domain is the medicated skincare market. This sector encompasses a wide array of products formulated with active pharmaceutical ingredients (APIs) designed to address various skin concerns, from acne and eczema to aging and hyperpigmentation. As consumers increasingly seek solutions that combine efficacy with safety and convenience, the demand for medicated skincare continues to surge. This paper explores the dynamics of the medicated skincare market, delving into key trends, innovations, and future prospects shaping its trajectory. The global medicated skincare market expanded at 5.7% CAGR from 2012 to 2022 and reached a size of US$ 36.7 billion in 2022. The market is predicted to grow at a CAGR of 8% to reach a valuation of US$ 84.2 billion by the end of 2033.
According to a new market research report, ‘Global Autoimmune Treatment Market (2009–2014)’, published by MarketsandMarkets, the global autoimmune treatment market is expected to be worth US$68.81 billion by 2014, with an estimated CAGR of 12.7% from 2009 to 2014. The North American market is expected to account for nearly 42% of the total revenues.
Apoptosis Market research report gives an insight into Apoptosis Mechanism, by Molecular Pathways, Caspase Activators and Inhibitors, Protease/Proteasome Inhibitors, Bcl-2 Modulators, p53 Modulators and Other. See Full Report @ http://bit.ly/1KdUj5P
According to the latest research report by IMARC Group, The global CBD skin care market size reached US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.4 Billion by 2032, exhibiting a growth rate (CAGR) of 18.33% during 2024-2032. More Info:- https://www.imarcgroup.com/cbd-skin-care-market